Avacta announces escalation in clinical study of AVA6000
AVA6000 is a novel form of doxorubicin that has been modified using Avacta’s delivery platform to improve safety
Read More
Tag: AVA600
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
